Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fish oil and ICDs

This article was originally published in The Tan Sheet

Executive Summary

Fish oil does not reduce the risk of ventricular tachycardia (VT) or ventricular fibrillation (VF) in patients with implantable cardioverter defibrillators (ICDs), according to a study in the June 15 Journal of the American Medical Association. Omega-3 fatty acid supplementation may even increase the risk in patients with ICDs, Merritt Raitt, MD, Oregon Health & Science University, et al., find. A randomized controlled trial involving 200 patients with ICDs and recent incidence of VT or VF were randomly assigned to 1.8 g of fish oil daily or placebo. After 24 months, 65% of patients taking fish oil had ICD therapy for VT or VF compared to 59% for the placebo group. Researchers noted that although they were unable to demonstrate an antiarrhythmic benefit for fish oil, the results do not negate the possible benefits of omega-3s on patients who have suffered heart attacks...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS098324

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel